Patrick Donnelly
Stock Analyst at Citigroup
(3.50)
# 879
Out of 5,148 analysts
371
Total ratings
48.74%
Success rate
4.97%
Average return
Main Sectors:
Stocks Rated by Patrick Donnelly
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDLN Medline | Maintains: Buy | $48 → $60 | $45.85 | +30.86% | 2 | Feb 26, 2026 | |
| SHC Sotera Health Company | Maintains: Buy | $21 → $23 | $15.91 | +44.56% | 4 | Feb 24, 2026 | |
| GH Guardant Health | Maintains: Buy | $135 → $150 | $92.23 | +62.64% | 12 | Feb 20, 2026 | |
| BRKR Bruker | Maintains: Neutral | $53 → $40 | $39.81 | +0.48% | 19 | Feb 13, 2026 | |
| QDEL QuidelOrtho | Maintains: Neutral | $23 → $30 | $22.60 | +32.74% | 7 | Feb 12, 2026 | |
| AVTR Avantor | Maintains: Neutral | $13 → $11 | $8.81 | +24.86% | 9 | Feb 12, 2026 | |
| DGX Quest Diagnostics | Maintains: Neutral | $190 → $215 | $210.25 | +2.26% | 12 | Feb 10, 2026 | |
| QGEN Qiagen | Maintains: Neutral | $55 → $55 | $48.83 | +12.64% | 15 | Feb 6, 2026 | |
| IQV IQVIA Holdings | Maintains: Neutral | $230 → $200 | $174.27 | +14.76% | 14 | Feb 6, 2026 | |
| TECH Bio-Techne | Maintains: Buy | $70 → $80 | $57.82 | +38.36% | 13 | Feb 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $660 → $685 | $508.58 | +34.69% | 22 | Jan 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $265 | $178.61 | +48.37% | 22 | Jan 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $300 | $200.17 | +49.87% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 | $23.14 | -22.21% | 13 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $21 | $10.56 | +98.86% | 5 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $165 → $185 | $118.17 | +56.55% | 27 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,600 → $1,700 | $1,325.09 | +28.29% | 15 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $375 | $279.59 | +34.12% | 17 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $375 | $267.56 | +40.16% | 17 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $225 → $200 | $108.27 | +84.72% | 10 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $42 | $20.66 | +103.29% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $60 → $80 | $75.45 | +6.03% | 15 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $85 → $80 | $132.89 | -39.80% | 17 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $285 → $265 | $206.00 | +28.64% | 12 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $75 | $103.35 | -27.43% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $28 | $15.09 | +85.55% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $135 → $145 | $95.59 | +51.69% | 1 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $265 → $300 | $307.23 | -2.35% | 24 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $9 | $2.96 | +204.05% | 6 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.75 → $2.75 | $2.25 | +22.49% | 4 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $250 → $260 | $286.47 | -9.24% | 11 | Feb 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $9.06 | -33.77% | 4 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $28 → $32 | $5.01 | +538.72% | 2 | Nov 30, 2018 |
Medline
Feb 26, 2026
Maintains: Buy
Price Target: $48 → $60
Current: $45.85
Upside: +30.86%
Sotera Health Company
Feb 24, 2026
Maintains: Buy
Price Target: $21 → $23
Current: $15.91
Upside: +44.56%
Guardant Health
Feb 20, 2026
Maintains: Buy
Price Target: $135 → $150
Current: $92.23
Upside: +62.64%
Bruker
Feb 13, 2026
Maintains: Neutral
Price Target: $53 → $40
Current: $39.81
Upside: +0.48%
QuidelOrtho
Feb 12, 2026
Maintains: Neutral
Price Target: $23 → $30
Current: $22.60
Upside: +32.74%
Avantor
Feb 12, 2026
Maintains: Neutral
Price Target: $13 → $11
Current: $8.81
Upside: +24.86%
Quest Diagnostics
Feb 10, 2026
Maintains: Neutral
Price Target: $190 → $215
Current: $210.25
Upside: +2.26%
Qiagen
Feb 6, 2026
Maintains: Neutral
Price Target: $55 → $55
Current: $48.83
Upside: +12.64%
IQVIA Holdings
Feb 6, 2026
Maintains: Neutral
Price Target: $230 → $200
Current: $174.27
Upside: +14.76%
Bio-Techne
Feb 5, 2026
Maintains: Buy
Price Target: $70 → $80
Current: $57.82
Upside: +38.36%
Jan 30, 2026
Maintains: Buy
Price Target: $660 → $685
Current: $508.58
Upside: +34.69%
Jan 16, 2026
Maintains: Buy
Price Target: $200 → $265
Current: $178.61
Upside: +48.37%
Jan 7, 2026
Initiates: Buy
Price Target: $300
Current: $200.17
Upside: +49.87%
Dec 11, 2025
Downgrades: Neutral
Price Target: $18
Current: $23.14
Upside: -22.21%
Dec 11, 2025
Upgrades: Buy
Price Target: $12 → $21
Current: $10.56
Upside: +98.86%
Nov 25, 2025
Maintains: Buy
Price Target: $165 → $185
Current: $118.17
Upside: +56.55%
Nov 10, 2025
Maintains: Buy
Price Target: $1,600 → $1,700
Current: $1,325.09
Upside: +28.29%
Oct 30, 2025
Maintains: Buy
Price Target: $350 → $375
Current: $279.59
Upside: +34.12%
Oct 30, 2025
Maintains: Buy
Price Target: $350 → $375
Current: $267.56
Upside: +40.16%
Aug 21, 2025
Downgrades: Neutral
Price Target: $225 → $200
Current: $108.27
Upside: +84.72%
Aug 13, 2025
Maintains: Buy
Price Target: $34 → $42
Current: $20.66
Upside: +103.29%
Jul 9, 2025
Upgrades: Buy
Price Target: $60 → $80
Current: $75.45
Upside: +6.03%
Jul 9, 2025
Downgrades: Sell
Price Target: $85 → $80
Current: $132.89
Upside: -39.80%
Jan 30, 2025
Maintains: Buy
Price Target: $285 → $265
Current: $206.00
Upside: +28.64%
Nov 6, 2024
Maintains: Buy
Price Target: $80 → $75
Current: $103.35
Upside: -27.43%
Aug 7, 2024
Maintains: Buy
Price Target: $30 → $28
Current: $15.09
Upside: +85.55%
Jul 30, 2024
Maintains: Buy
Price Target: $135 → $145
Current: $95.59
Upside: +51.69%
Dec 11, 2023
Maintains: Neutral
Price Target: $265 → $300
Current: $307.23
Upside: -2.35%
Dec 11, 2023
Maintains: Buy
Price Target: $7 → $9
Current: $2.96
Upside: +204.05%
Aug 10, 2023
Maintains: Neutral
Price Target: $3.75 → $2.75
Current: $2.25
Upside: +22.49%
Feb 17, 2023
Maintains: Neutral
Price Target: $250 → $260
Current: $286.47
Upside: -9.24%
Nov 3, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $9.06
Upside: -33.77%
Nov 30, 2018
Upgrades: Neutral
Price Target: $28 → $32
Current: $5.01
Upside: +538.72%